Revvity Clears FDA Hurdle for Automated Testosterone Testing Suite
Event summary
- Revvity's subsidiary IDS received FDA clearance for its Total Testosterone automated chemiluminescence immunoassay (ChLIA) on May 13, 2026.
- The clearance complements existing FDA-cleared ChLIA tests for free testosterone and SHBG, creating a comprehensive testosterone testing solution on a single platform.
- The portfolio enables first- and second-line diagnostic testing for hypogonadism, replacing complex ED-LC/MS methods with streamlined workflows.
- Revvity reported 2025 revenue of $2.9 billion with approximately 11,000 employees.
The big picture
Revvity's FDA clearance positions it as a key player in the automated endocrine testing market, addressing workflow inefficiencies in diagnosing androgen-related conditions. The clearance aligns with broader industry trends toward automation and integration in diagnostic workflows, potentially disrupting traditional testing methods. With a substantial revenue base and global reach, Revvity is well-positioned to capitalize on this strategic advantage.
What we're watching
- Market Adoption
- The pace at which diagnostic labs and healthcare providers transition from ED-LC/MS methods to Revvity's automated platform.
- Competitive Response
- Whether competitors in the endocrine testing space introduce competing automated solutions or seek partnerships.
- Portfolio Expansion
- How Revvity leverages this clearance to expand its reproductive endocrine disorders portfolio further.
Related topics